BlackRock
NVCR icon

BlackRock’s NovoCure NVCR Stock Holding History

BlackRock’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$144M Sell
13,193,765
-347,683
-3% -$4.34M ﹤0.01% 1882
2025
Q4 		$175M Sell
13,541,448
-406,110
-3% -$5.21M ﹤0.01% 1768
2025
Q3 		$180M Sell
13,947,558
-166,926
-1% -$2.23M ﹤0.01% 1726
2025
Q2 		$251M Buy
14,114,484
+1,086,692
+8% +$18.9M ﹤0.01% 1488
2025
Q1 		$232M Buy
13,027,792
+1,294
+0% +$29.4K ﹤0.01% 1508
2024
Q4 		$388M Buy
13,026,498
+247,308
+2% +$5.23M 0.01% 1246
2024
Q3 		$200M Buy
12,779,190
+646,793
+5% +$11.7M ﹤0.01% 1661
2024
Q2 		$208M Buy
12,132,397
+3,047,985
+34% +$53.6M ﹤0.01% 1594
2024
Q1 		$142M Buy
9,084,412
+292,377
+3% +$4.3M ﹤0.01% 1860
2023
Q4 		$131M Buy
8,792,035
+929,654
+12% +$12.4M ﹤0.01% 1926
2023
Q3 		$127M Sell
7,862,381
-258,636
-3% -$7.46M ﹤0.01% 1851
2023
Q2 		$337M Sell
8,121,017
-203,904
-2% -$12.7M 0.01% 1207
2023
Q1 		$501M Buy
8,324,921
+719,265
+9% +$57.5M 0.01% 918
2022
Q4 		$558M Buy
7,605,656
+225,711
+3% +$17M 0.02% 806
2022
Q3 		$561M Buy
7,379,945
+46,794
+0.6% +$3.65M 0.02% 751
2022
Q2 		$510M Buy
7,333,151
+600,638
+9% +$45.2M 0.02% 839
2022
Q1 		$558M Buy
6,732,513
+43,157
+0.6% +$3.18M 0.02% 890
2021
Q4 		$502M Sell
6,689,356
-34,324
-0.5% -$3.45M 0.01% 1023
2021
Q3 		$781M Buy
6,723,680
+203,900
+3% +$30.8M 0.02% 692
2021
Q2 		$1.45B Buy
6,519,780
+94,820
+1% +$18.4M 0.04% 453
2021
Q1 		$849M Buy
6,424,960
+628,280
+11% +$99.4M 0.03% 666
2020
Q4 		$1B Sell
5,796,680
-179,626
-3% -$24.6M 0.03% 535
2020
Q3 		$665M Buy
5,976,306
+1,676,559
+39% +$134M 0.02% 607
2020
Q2 		$255M Sell
4,299,747
-1,370,939
-24% -$90.2M 0.01% 1183
2020
Q1 		$382M Sell
5,670,686
-62,631
-1% -$4.95M 0.02% 758
2019
Q4 		$483M Sell
5,733,317
-188,517
-3% -$15.2M 0.02% 825
2019
Q3 		$443M Buy
5,921,834
+367,202
+7% +$29.4M 0.02% 827
2019
Q2 		$351M Buy
5,554,632
+750,374
+16% +$38M 0.02% 1018
2019
Q1 		$231M Buy
4,804,258
+7,570
+0.2% +$364K 0.01% 1301
2018
Q4 		$161M Buy
4,796,688
+46,754
+1% +$1.71M 0.01% 1480
2018
Q3 		$249M Buy
4,749,934
+129,388
+3% +$5.15M 0.01% 1311
2018
Q2 		$145M Buy
4,620,546
+846,277
+22% +$23.5M 0.01% 1684
2018
Q1 		$82.3M Sell
3,774,269
-31,827
-0.8% -$685K ﹤0.01% 1973
2017
Q4 		$76.9M Sell
3,806,096
-120,358
-3% -$2.32M ﹤0.01% 2025
2017
Q3 		$77.9M Buy
3,926,454
+133,336
+4% +$2.62M ﹤0.01% 1999
2017
Q2 		$65.6M Buy
3,793,118
+367,601
+11% +$4.75M ﹤0.01% 2067
2017
Q1 		$27.7M Buy
3,425,517
+3,421,462
+84,376% +$24.7M ﹤0.01% 2563
2016
Q4 		$32K Sell
4,055
-802
-17% -$6.45K ﹤0.01% 3111
2016
Q3 		$42K Sell
4,857
-970
-17% -$8.85K ﹤0.01% 3046
2016
Q2 		$68K Buy
5,827
+5,390
+1,233% +$67.5K ﹤0.01% 2781
2016
Q1 		$6K Buy
+437
New +$6.27K ﹤0.01% 3325

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock's NVCR Position: Q1 2026 in Review

BlackRock reduced its NovoCure (NVCR) stake by 2.6% in Q1 2026, selling an estimated $4.34M and leaving 13,193,765 shares worth $144M. The position accounts for ﹤0.01% of the portfolio, ranked #1882.

BlackRock first reported a position in NVCR in Q1 2016 and has held it in 41 quarters since. The position peaked at $1.45B in Q2 2021. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • BlackRock held 13,193,765 shares of NovoCure worth $144M as of Q1 2026.
  • BlackRock sold 347,683 NovoCure shares in Q1 2026, an estimated $4.34M.
  • NovoCure made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #1882 holding.
  • BlackRock first reported a position in NovoCure in Q1 2016 and has held it in 41 quarters since.
  • BlackRock's NovoCure position peaked at $1.45B in Q2 2021.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.